I don't say too much here because as Dirty Harry says, "A man's got to know his limitations" but I remember from years ago, maybe earlyish 2020 that if all else failed getting Zantrene approved as a chemotherapeutic for AML only would be worth $12 per share. Now the SOI haven't increased that much since then so that has always been the minimum figure I would consider based on the company's prospects at the time. Obviously I would be guided by the board. Hopefully some others remember this maybe other long termers like Titans, II, John, LT or Eddy to name a few. I'm still very confident that we'll get a transaction and for me the opportunity cost is not being in RAC when that time comes. My dodgy memory and opinion only. Have a great 2023 everyone.
Ann: Letter to Shareholders, Notice of Meeting & Proxy Form, page-40
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |